UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results for Q4 2025 on Wednesday, February 25th. The company reported earnings of $7.70 per share, beating estimates of $7.33 by $0.37. The company also reported revenue of $790,200,000, missing estimates of $829,338,815 by $-39,138,815.
You can see Quiver Quantitative's $UTHR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UNITED THERAPEUTICS Insider Trading Activity
UNITED THERAPEUTICS insiders have traded $UTHR stock on the open market 581 times in the past 6 months. Of those trades, 0 have been purchases and 581 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:
- MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 210 sales selling 503,315 shares for an estimated $230,155,271.
- MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 195 sales selling 278,000 shares for an estimated $125,480,869.
- JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 74 sales selling 129,517 shares for an estimated $60,347,867.
- PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 85 sales selling 112,900 shares for an estimated $51,723,535.
- LOUIS W SULLIVAN has made 0 purchases and 2 sales selling 5,950 shares for an estimated $3,047,200.
- TOMMY G THOMPSON has made 0 purchases and 2 sales selling 5,470 shares for an estimated $2,294,854.
- CHRISTOPHER CAUSEY has made 0 purchases and 5 sales selling 5,000 shares for an estimated $2,209,644.
- JUDY D. OLIAN sold 1,800 shares for an estimated $747,767
- CHRISTOPHER PATUSKY sold 1,000 shares for an estimated $495,953
- JAN MALCOLM has made 0 purchases and 5 sales selling 900 shares for an estimated $376,741.
- NILDA MESA sold 187 shares for an estimated $90,064
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
UNITED THERAPEUTICS Hedge Fund Activity
We have seen 443 institutional investors add shares of UNITED THERAPEUTICS stock to their portfolio, and 366 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 1,042,711 shares (+74.5%) to their portfolio in Q4 2025, for an estimated $508,060,934
- DARWIN GLOBAL MANAGEMENT, LTD. removed 748,550 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $364,730,987
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 609,421 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $296,940,382
- AVORO CAPITAL ADVISORS LLC added 583,838 shares (+28.9%) to their portfolio in Q4 2025, for an estimated $284,475,065
- CITIGROUP INC removed 367,062 shares (-66.6%) from their portfolio in Q4 2025, for an estimated $178,850,959
- JANUS HENDERSON GROUP PLC added 341,383 shares (+75.1%) to their portfolio in Q4 2025, for an estimated $166,338,866
- BAILLIE GIFFORD & CO added 323,016 shares (+inf%) to their portfolio in Q4 2025, for an estimated $157,389,546
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
UNITED THERAPEUTICS Government Contracts
We have seen $1,216,003 of award payments to $UTHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TYVASO KITS & CARTRIDGES: $379,307
- OPSUMIT 10MG-QTY 4 @ $6,270.03 ADEMPAS 1MG, QTY 1 @ $12,153.05 REMODULIN 5MG/ML INJ 20ML VIAL, QTY 1 @ $6,2...: $49,773
- OPSUMIT 10MG-QTY 2 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 JULY 2025: $37,233
- OPSUMIT 10MG-QTY 4 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 SEPT FY25: $37,233
- TYVASO 64 MCG KIT: $17,351
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
UNITED THERAPEUTICS Congressional Stock Trading
Members of Congress have traded $UTHR stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
UNITED THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $UTHR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/06/2026
- HC Wainwright & Co. issued a "Buy" rating on 10/30/2025
- RBC Capital issued a "Outperform" rating on 10/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/10/2025
- Jefferies issued a "Buy" rating on 09/02/2025
To track analyst ratings and price targets for UNITED THERAPEUTICS, check out Quiver Quantitative's $UTHR forecast page.
UNITED THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $UTHR recently. We have seen 11 analysts offer price targets for $UTHR in the last 6 months, with a median target of $525.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $645.0 on 01/06/2026
- Lisa Walter from RBC Capital set a target price of $587.0 on 10/30/2025
- Benjamin Burnett from Wells Fargo set a target price of $423.0 on 10/30/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $525.0 on 10/30/2025
- Terence Flynn from Morgan Stanley set a target price of $435.0 on 10/10/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $525.0 on 09/10/2025
- Andreas Argyrides from Oppenheimer set a target price of $575.0 on 09/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
